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INTRODUCTION
Acute lymphoblastic leukemia (ALL) can be cured by
intensive chemotherapy in most children and a minority of
adults. However, high-risk features predict relapse and
define a subset of patients for whom bone marrow trans-
plantation (BMT) offers a unique chance for extended
leukemia-free survival [1-9]. For patients lacking a related
histocompatible donor, autologous (Auto) BMT [10-15],
peripheral blood stem cell transplantation, or alternatively,
unrelated donor (URD) marrow for allogeneic BMT are
available options, along with haploidentical related donor or
cord blood transplantation [16-22]. Auto transplantation
generally results in less transplantation-related mortality
(TRM) but lacks an allogeneic antileukemic effect. High
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ABSTRACT
For patients with high-risk or relapsed acute lymphoblastic leukemia (ALL) lacking a related histocompatible donor,
autologous (Auto) and unrelated donor (URD) transplantation are available options. We compared outcomes and
toxicities in 712 patients with ALL (517 URD, 195 Auto) in first complete remission (CR1) or second complete
remission (CR2) who underwent transplantation. All patients were <50 years old, although URD patients were
younger (median age, 14 versus 18 years, P < .002). The proportion of patients in CR1 versus CR2 was similar (36%
versus 38%, P = .57), but more URD recipients than Auto recipients had high-risk karyotypes (25% versus 13%, P =
.003) and white blood cell (WBC) counts ≥50 × 109/L (33% versus 14%, P < .001). Engraftment was similar in URD
and Auto recipients. Ex vivo purging delayed but did not prevent engraftment after Auto transplantation. Transplan-
tation-related mortality was higher after URD transplantation (42% ± 8%) than after Auto transplantation (20% ± 12%)
in CR1 (P = .004) and also in CR2. Conversely, relapse was more frequent after Auto transplantation in CR1 (Auto,
49% ± 12% versus URD, 14% ± 5%) and CR2 (64% ± 8% versus 25% ± 5%) (P < .0001). These findings showed net
similar outcomes for these 2 transplantation choices. Transplantation in CR1 yielded similar 3-year survival rates for
URD (51% ± 7%) and Auto (44% ± 12%), as did transplantation in CR2 (40% ± 6% versus 32% ± 9%, respectively).
Multivariate regression analysis identified significantly better disease-free survival after the first 6 months in
matched URD versus Auto in younger patients, in those in CR2 with CR1 >1 year, WBC <50 × 109/L, performance
status ≥90%, and in those who have undergone transplantation since 1995. These comparative data suggest that
both matched URD and Auto transplantation can yield extended survival. Although URD transplantation offers sub-
stantially better protection against leukemic relapse, improvements in allotransplantation safety and refinements in
patient selection are required to better aid treatment decision making for the best overall survival.
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TRM resulting from rejection, graft-versus-host disease
(GVHD), and posttransplantation immunodeficiency limit
survival after URD allografts, but a potent graft-versus-
leukemia (GVL) effect may prevent relapse.
The comparative magnitude of this antileukemic effect
versus the life-threatening or morbid complications of trans-
plantation must be balanced to provide patients with the best
treatment choices and superior clinical outcomes. We com-
pared the major clinical consequences of Auto and allogeneic
URD BMT to assess the differential morbidity, safety, and
antileukemic efﬁcacy of these transplantation choices.
PATIENTS AND METHODS
A total of 712 patients with ALL who were ≤50 years of
age at the time of transplantation were studied. All received
initial transplants during their first complete remission
(CR1) or second complete remission (CR2) between January
1989 and December 1998. The patient group included
517 patients receiving BMT from HLA-matched allogeneic
URD facilitated by the National Marrow Donor Program
using techniques for donor identiﬁcation, evaluation, marrow
collection, processing, and transport as reported previously
[23]. All recipient-donor pairs were matched serologically at
HLA-A, B and were matched using molecular typing for
DRβ1 alleles. Auto BMT recipients (n = 195) underwent
transplantation in 49 centers with data reported to the
Autologous Blood and Marrow Transplant Registry. Forty-
four patients received autologous transplants using blood-
derived stem cells; 138 patients received BM; and 13 patients
received blood and marrow. All URD recipients received
BM grafts. A minority (less than one third) of the patients
were included in an earlier analysis [19]. Clinical character-
istics of the 2 patient groups are shown in Table 1 with com-
parisons using the chi-square test (for categorical) or the
Wilcoxon rank-sum test (for continuous variables).
Engraftment was defined as the time to recovery of
>500 neutrophils/µL for the ﬁrst of 3 serial measures. Platelet
recovery was deﬁned as platelet count >50 × 109/L indepen-
dent of transfusions. GVHD was graded by standard methods
and reported to the National Marrow Donor Program in
standardized fashion as described [7,19,23]. TRM was deﬁned
as death in continuous CR. Survival and disease-free survival
(DFS) rates (without posttransplantation relapse) were calcu-
lated from the day of transplantation to the last follow-up at
which the patient was alive (or alive in remission). Patients
with missing relapse status (n = 7) were not included in the
outcome analysis of DFS, relapse, or treatment-related mor-
tality. Three patients with missing engraftment status were
not evaluated in analyses of posttransplantation engraftment.
Table 1. Patient Characteristics
No. Autologous BMT Unrelated Donor Allogeneic BMT
Evaluable* Total CR1 CR2 Total CR1 CR2 P†
n 195 517
Age, median (range), y 18 (1-50) 28 (0-51) 11 (0-50) 14 (1-50) 18 (0-50) 13 (0-51) .002
No. of patients aged <20 y 111 (57%) 28% 75% 332 (64%) 54% 70% .07
Male patients, % (M:F, n) 66 (129:66) 68 65 57 (295:222) 56 58 .03
CR1, % 38 36 .57
Time from diagnosis to BMT (CR1), mo 2-40 (7) 3-51 (7) .42
Duration of CR1 for BMT in CR2, range 381/450 7-416 (94) 3-765 (93) .62 
(median), wk
Disease lineage 480/712
B-lineage, % 78 64 86 82 82 82 .24
T-lineage, % 22 36 14 18 18 18
WBC at diagnosis ≥50 × 109/L, % (n) 579/712 14 (23) 21 9 33 (136) 44 27 <.001
Karyotype, %
High risk 13 20 10 25 52 10 .003
t(9;22) 4 8 1 14 31 5
t(4;11) or 11q32 1.5 4 0 9 18 3
t(8;14) 3 4 3 <1 0 <1
t(1:19) 3 4 3 <1 1 1
Hypodiploid 1.5 0 3 1 2 1
Other abnormal 22 15 27 16 10 20
Normal 22 23 22 16 5 23
Unknown 43 43 43 43 35 47
Extramedullary leukemia pre-BMT, % 20 17 22 15 17 14 .15
TBI in conditioning, % 65 49 75 90 87 91 <.001
Autologous purged ex vivo, % (n) 57 (111) 45 66 —
Ex vivo T-cell depletion, % (n) — 29 (152) 28 30
Transplantation date 1989-1995 81 71 88 44 41 47 <.001 
(versus 1996-1998), %
Recipient CMV positive, % 701/712 42 54 35 35 39 32 <.001
Karnofsky score 90%-100%, % 678/712 80 80 80 80 83 78 .98
*The number of evaluable/eligible patients (if data elements were missing) is shown.
†P values represent comparison of patient characteristics between autologous and URD transplantation recipients.
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Time-to-event curves were calculated by the method of
Kaplan and Meier [24]. For events (engraftment, relapse, or
TRM) in which early competing hazards (death or relapse,
as appropriate) would censor patients, the cumulative inci-
dence method was employed [25]. Ninety-ﬁve percent con-
ﬁdence limits were calculated from the standard errors using
the Greenwood formula (Kaplan and Meier) or an analogous
ﬁrst-order Taylor series for cumulative incidence. Multiple
variable analyses were performed using logistic regression
for calculations of neutrophil engraftment or the Cox pro-
portional hazards model for other outcomes of interest
[26,27]. Patients who died on or before day 21 (2 patients
with Auto and 23 patients with URD transplantation) were
unevaluable for engraftment, whereas patients without
engraftment (13 patients with Auto and 4 patients with
URD transplantation) were analyzed as having graft failure
in the logistic regression. Forward step-wise regression
analyses including testing the proportional hazards assump-
tion and testing for interactions between variables were per-
formed. Variables tested in regression modeling were those
listed in Table 1. Regression variables with missing data
included an indicator for the missing data elements. As
needed, time-dependent covariates (eg, GVHD) were added
to explain time-varying effects of relevant covariates as well
as stratiﬁed analysis for variables not ﬁtting the proportional
hazards assumptions. As identiﬁed in the regression model
for DFS, factors significantly associated with DFS were
combined. Kaplan-Meier probabilities of DFS after either
transplantation type were calculated for patients with and
without the adverse prognostic factors identiﬁed in the mul-
tivariate analysis.
RESULTS
Patient Characteristics and Transplantation
Techniques
Comparison of the 2 cohorts (Table 1) including
195 Auto transplant recipients and 517 URD allogeneic trans-
plant recipients showed that Auto recipients were slightly
older (median age, 18 versus 14 years, P = .002) and that a
slightly smaller proportion of Auto recipients were younger
than 20 years (57% versus 64%, P = .07). A larger fraction of
Auto patients were males (66% versus 57%, P = .03).
Characteristics of the leukemia in the 2 groups differed
somewhat as well. A smaller percentage of Auto transplant
recipients had an elevated leukocyte count (≥50 × 109/L) at
the time of diagnosis (14% versus 33% of URD recipients,
P < .001). High-risk karyotypic features [t(9;22); t(4;11) or
11q32; t(1:19) or hypodiploid] were recognized in 13% of
Auto and 25% of URD recipients (P = .003). Auto trans-
plantations were more frequently performed in the earlier
years of study, with 81% of Auto transplantations done
between 1989 and 1995 versus only 44% of URD transplan-
tations (P < .001). Only 65% of Auto transplantations versus
90% of URD transplantations were performed using total
body irradiation (TBI) during pretransplantation condition-
ing (P < .001). A higher proportion of Auto recipients were
cytomegalovirus (CMV) seropositive pre-BMT (40% versus
35% of URD recipients, P < .001).
Engraftment
Neutrophil recovery representing hemopoietic engraft-
ment was observed in 667 evaluable patients (98%).
Engraftment was quicker after URD BMT or unpurged Auto
transplantation versus purged Auto transplantation (Fig-
ure 1A). As shown in Table 2, graft failure was more likely
after purged or unpurged Auto transplantation than after
URD transplantation (P = .01). Factors not associated with
the speed or completeness of engraftment (not shown) were
patient age, sex, cytogenetic phenotype, white blood cell
(WBC) count at diagnosis, immunophenotype, remission
status, or conditioning regimen with or without TBI or T-cell
depletion (in URD recipients).
Although delayed neutrophil recovery was more fre-
quent after purged Auto transplantation (P < .0001 at day
45), eventual neutrophil recovery was complete in nearly all
patients by day 100 (Figure 1A). Most URD recipients (99%
± 1%), unpurged Auto recipients (95% ± 4%), and ex vivo
purged Auto recipients (89% ± 5%) recovered neutrophil
production by day 100 (P = .09). In contrast, recovery of
Figure 1. A, The cumulative incidence plots of engraftment (neu-
trophils >500/µL) in URD (n = 493), purged Auto (n = 110), and
unpurged Auto (n = 78) BMT recipients (P < .0001 at day 45; P = .09
at day 100). B, Platelet recovery (to 50 × 109/L) was slower and less
complete after URD versus Auto BMT: at 12 months, 69% ± 3% of
URD recipients and 89% ± 8% of Auto recipients had platelet recov-
ery (CR1, P = .05; CR2, P < .0001). Data for platelet recovery to this
level were available in 432 URD recipients (84%) but only 64 Auto
recipients (34%).
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platelet production to a sustained platelet count >50 × 109/L
was signiﬁcantly slower and less frequent after URD BMT.
At 12 months post-BMT, 89% ± 8% of Auto recipients but
only 69% ± 3% of URD recipients had platelet recovery
(Figure 1B, P < .0001). Multivariate analysis (Table 2) iden-
tiﬁed signiﬁcantly slower and incomplete platelet recovery
after URD BMT (within the first 2 months), in older
patients, and after transplantations performed from 1989 to
1995. The impact of purging could not be evaluated because
too few purged Auto patients (n = 11) had platelet recovery
data reported.
Transplantation-Related Mortality
Death during continued posttransplantation remission
(TRM) occurred in 217 patients (30%) at a median of 67 days
(range, 1-3140 days) following BMT. As shown in Figure 2,
for both patients in CR1 and those in CR2, TRM was
significantly higher after URD transplantation than after
Auto transplantation. By 5 years post-BMT, the incidence of
TRM was 42% ± 8% of URD recipients versus 20% ± 12%
of Auto recipients (P = .004) who received transplants dur-
ing CR1 and was 40% ± 6% of URD recipients versus 9% ±
5% of Auto recipients (P < .0001) who received transplants
during CR2. Multivariate analysis (Table 2) demonstrated
significantly higher TRM after URD transplantation, in
older patients, and after BMT performed from 1989 to
1995. Neither remission number, pretransplantation
Karnofsky status, CMV serostatus, use of TBI in condition-
ing, T-cell depletion, nor other leukemia-speciﬁc character-
istics (cytogenetics, immunophenotype, WBC at diagnosis)
modiﬁed the risk of TRM. In the URD recipients, GVHD
unfavorably increased TRM. Cox regression analysis
demonstrated that patients with acute GVHD (grades II-IV)
had a relative risk (RR) of TRM of 2.93 (range, 2.12-4.06,
P = .0001) and those with chronic GVHD had an RR of
TRM of 1.72 (range, 1.07-2.79, P = .03) compared to
patients without acute or chronic GVHD.
Relapse
Recurrent leukemia developed in only a minority of
URD recipients: 14% ± 5% of those receiving transplants in
CR1 and 25% ± 5% of those receiving transplants in CR2 at
5 years. In contrast, Auto transplantation was followed by a
significantly more frequent risk of relapse compared with
URD transplantation (49% ± 12% of those receiving trans-
plants in CR1, 64% ± 8% of those receiving transplants in
Table 2. Clinical Outcomes: Multivariate Analysis*
A. Engraftment
Odds Ratio of
Graft Failure 95% CI P
Unpurged autologous 1.0 — —
Purged autologous 1.72 .51-5.78 .38
URD .16 .04-.64 .01
B. Platelet recovery
RR of Platelet
Recovery 95% CI P
Autologous 1.0 — —
URD (<2 mo post-BMT) .52 .38-.72 <.0001
URD (≥2 mo post-BMT) .68 .36-1.28 .23
Age ≤20 y versus >20 y 1.43 1.14-1.79 .002
BMT 1989-1995 versus 1996-1998 .75 .60-.94 .01
C. Transplantation-related mortality
RR of Death
in Remission 95% CI P
URD (versus Auto) 4.1 2.61-6.45 <.0001
Age ≤20 years .62 .47-.82 .0007
BMT 1989-1995 1.52 1.15-2.02 .004
D. Relapse
RR of
Relapse 95% CI P
WBC <50 × 109/L 1.0 — —
WBC ≥50 × 109/L 2.28 1.46-3.57 .0003
Recipient CMV seropositive 1.50 1.12-2.0 .006
WBC <50 × 109/L†
Autologous 1.0 — —
URD .25 .17-.36 .0001
WBC ≥50 × 109/L†
Autologous 1.0 — —
URD .59 .27-1.28 .18
*For engraftment, the odds ratio for graft failure (no neutrophil
recovery) in multivariate logistic regression along with the 95% conﬁ-
dence interval (CI) and P value are shown. For platelet recovery, Cox
multivariate regression–derived RR for platelet recovery to >50 × 109/L
is shown based on available platelet recovery data for URD (n = 432)
and Auto (n = 64) transplantation groups. For transplantation-related
mortality, the RR for TRM stratiﬁed (because of proportional hazards
violations) by sex and by disease status (CR1 ≤7 months to BMT, CR1
>7 months, CR2; 3 groups) is shown. For relapse, the RR for relapse
stratified (due to proportional hazards violations) by disease status
(CR1, CR2 with CR1 <1 year, and CR2 with CR1 ≥1 year; 3 groups)
and disease lineage is shown.
†Risk ratio is shown separately for WBC < or ≥50 × 109/L in URD
because of a statistically signiﬁcant interaction between WBC and trans-
plantation type (P = .04). For Auto cases, the RR of relapse of WBC ≥50
× 109/L (compared to WBC < 50 × 109/L) is .96 (.46-1.98; P = .9).
Figure 2. Treatment-related mortality was markedly greater after
URD than after Auto BMT. At 5 years, URD BMT resulted in 42% ±
8% TRM for CR1 and 40% ± 6% TRM for CR2 versus 20% ± 12%
TRM for CR1 and 9% ± 5% TRM for CR2 after Auto BMT (CR1,
P = .004; CR2, P < .0001).
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CR2, both P < .0001 for comparison with URD transplant
recipients) (Figure 3). As shown in Table 2, multivariate
analysis identified a significantly higher risk of relapse in
patients with WBC ≥50 × 109/L at diagnosis and a signiﬁ-
cantly lower risk of relapse after URD versus Auto trans-
plantation. The protection was most notable in patients
with WBC <50 × 109/L at diagnosis. For patients with
higher WBC at diagnosis, URD transplantation, though
still superior to autografting, was less effective in preventing
relapse. Somewhat unexpectedly, relapse was also more fre-
quent in patients who were CMV seropositive [28].
Other factors, including age (P = .72), high-risk kary-
otype (P = .42), TBI conditioning (P = .18), purging the
autografts, T-cell depletion of the allografts, and the devel-
opment of acute or chronic GVHD, did not significantly
impact the risk of relapse. Among patients receiving trans-
plants during CR2, duration of CR1 was not associated with
differences in relapse risk for either Auto or URD patients
at 5 years (Auto CR1 <1 year relapse, 61% ± 16% versus
CR1 >1 year, 66% ± 10%; URD CR1 <1 year relapse, 32% ±
9% versus CR1 >1 year, 23% ± 6%). URD transplantation
led to a significantly lower risk of relapse in both cohorts
(P < .002). During the ﬁrst year post-BMT, the protection
against relapse with URD (versus Auto) transplantation was
most prominent. URD transplantation led to a lower RR of
relapse in B-lineage of .20 (95% CI, .13-.30, P < .0001) and
in unknown lineage of .29 (95% CI, .16-.51, P < .0001) but
not in T-lineage leukemia, with an RR of .83 (95% CI, .38-
1.8, P = .63). This ﬁnding was independent of the associa-
tion between T-lineage ALL and high WBC.
Survival and DFS
These differing influences of higher TRM after URD
transplantation yet lower relapse after URD transplantation
yielded a DFS rate that was similar using either transplanta-
tion technique during CR1 or CR2. As shown in Figure 4,
for CR1 patients, the 5-year probability of DFS was 44% ±
8% with URD BMT versus 31% ± 14% with Auto BMT
(P = .46). In CR2, transplantations yielded a 5-year DFS
after URD transplantation of 36% ± 6% versus 27% ± 8%
after Auto transplantations (P = .11). In the univariate analysis,
CR2 patients who received transplants after a long (≥1 year)
CR had slightly better 5-year DFS rates (URD, 38% ± 8%;
Auto, 27% ± 10%). The Cox multiple variable analysis
(Table 3) demonstrates a signiﬁcantly superior DFS rate after
URD transplantation than after Auto transplantation among
patients who survive the ﬁrst 6 months posttransplantation.
Superior DFS was also observed in CR1 patients and in CR2
patients who underwent transplantation after a ≥1 year initial
remission (compared to those with a short CR1), in those
with Karnofsky score >90% at transplantation, in patients
with WBC <50 × 109/L at diagnosis, in patients <20 years of
age, and in patients who received transplants between 1996
and 1998. High-risk karyotype, CMV serology, and
immunophenotype (T- versus B-lineage) had no additional
impact on predicting DFS after transplantation. In the URD
transplant recipients, the development of acute GVHD
(grades II-IV) was associated with poorer DFS (RR of treat-
ment failure, 1.82 [range, 1.41-2.35], P = .0001). A similar
Figure 3. Relapse was less frequent after URD BMT in CR1 (P <
.0001) and CR2 (P < .0001) than after Auto BMT.
Figure 4. Disease-free survival after URD versus Auto BMT. Outcomes were similar with either approach (CR1, P = .46; CR2, P = .11).
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regression model (Table 3) demonstrated superior survival in
Auto transplantation patients within the ﬁrst 6 months, but
beyond the ﬁrst 6 months, subsequent survival was higher in
URD recipients. Additionally, post-BMT survival was
signiﬁcantly better during CR1, in patients with a long initial
remission (who received transplants during CR2), in those
younger than 20 years, and in patients receiving transplants
between 1996 and 1998.
These regression analyses defined risk factors associ-
ated with distinctly different DFS rates after transplanta-
tion. Using the independently significant factors of initial
remission duration of >1 year, WBC <50 × 109/L, and
Karnofsky score ≥90%, groups with 0, 1, or ≥2 high-risk
factors were examined for their outcomes. As shown (Fig-
ure 5), patients lacking all of these high-risk factors had
3-year DFS rates of 51% ± 8% after URD and 31% ± 11%
after Auto BMT. Patients with 1 risk factor had DFS rates
of 42% ± 8% after URD and 41% ± 15% after Auto BMT;
≥2 risk factors led to DFS rates of 25% ± 11% after URD
and 20% ± 25% after Auto BMT. Only in the most favor-
able group (no risk factors) was URD BMT associated with
a superior outcome compared to Auto BMT. This associa-
tion was apparent in both older and younger patients (for
no risk factors, URD in patients >20 years [n = 58], 48% ±
13%; URD in patients ≤20 years [n = 117], 53% ± 10%;
Auto in patients >20 years [n = 36], 32% ± 17%; Auto in
patients ≤20 years [n = 41], 30% ± 14%). Patients with 1 or
≥2 risk factors in either age group had similar outcomes
with URD or Auto BMT (not shown).
DISCUSSION
In this study, direct and risk-adjusted comparisons of
outcome were performed to define the patients with ALL
most likely to beneﬁt from either URD allogeneic or Auto
BMT. The superior antileukemic potency of URD trans-
plantation was associated with better protection against
leukemia relapse but could not overcome leukemia with cer-
tain adverse prognostic factors (particularly extreme leuko-
cytosis), which are markers of highly resistant ALL. Thus,
although relapse risks were substantially and significantly
lower after URD transplantation, nearly one third of
patients with an elevated WBC or short initial remission still
relapsed after URD transplantation. In contrast, recurrent
Figure 5. Disease-free survival after either URD or Auto BMT using risk factors of short (<1 year) initial remission, WBC ≥50 × 109/L and/or Karnof-
sky <90% to compare DFS for patients with 0, 1, or ≥2 risk factors. Because of missing data for one or more risk factors, 199 patients were not included.
Table 3. Survival and Disease-Free Survival: Multivariate Analysis*
Disease-Free Survival
RR of Relapse
or Death 95% CI P
Autologous 1.0 — —
URD within first 6 mo post-BMT .99 .75-1.30 .93 
versus Auto
URD >6 mo post-BMT versus Auto .64 .44-.92 .02
Age ≤20 y .76 .62-.95 .01
Karnofsky score 90%-100% .77 .61-.98 .03
WBC ≥50 × 109/L 1.30 1.02-1.66 .04
BMT from 1989-1995 1.28 1.04-1.59 .02
CR1 ≥1 y (CR2 patients) 1.0 — —
CR1 <1 year (CR2 patients) 1.37 1.04-1.79 .02
CR1 .72 .56-.91 .007
Survival
RR of
Death 95% CI P
Autologous 1.0 — —
URD within first 6 mo post-BMT 1.79 1.28-2.50 .0006 
versus Auto
URD >6 mo post-BMT versus Auto .56 .41-.77 .0003
Age ≤20 years .69 .56-.85 .0004
BMT 1989-1995 1.32 1.06-1.64 .01
CR1 ≥1 year (CR2 patients) 1.0 — —
CR1 <1 year (CR2 patients) 1.53 1.16-2.01 .002
CR1 .78 .61-.99 .04
*Shown are results of Cox multivariate regression models for disease-
free survival (stratiﬁed by sex and controlled for remission number) and
survival (stratified by sex and controlled for remission number). The
impact of remission number and duration of CR1 (for transplantations
during CR2) are shown adjusted for other significant factors in the
regression models. 
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leukemia was overwhelmingly the major reason for failure
after autografting in all patient subsets.
The clinical beneﬁt of URD transplantation is still limited
by excessive (approximately 40%) TRM. Encouragingly,
TRM was signiﬁcantly lower in more recent years, but sub-
stantial improvements in supportive care plus protection
against persistent GVHD and ongoing immunodeﬁciency will
be required before the potent antileukemic beneﬁts of URD
transplantation can enhance survival for a larger fraction of
patients. Although the highest risk for TRM was apparent in
the ﬁrst 3 months posttransplantation, an additional 15% to
20% of patients died without relapse between 3 and 12 months
posttransplantation, which shows the substantial need for
greater protection against late lethal transplantation events.
Although initial graft failure was uncommon, prolonged
thrombocytopenia after URD transplantation was also appar-
ent, with nearly 40% of patients remaining significantly
thrombocytopenic by 10 to 12 months posttransplantation.
These distinct causes of treatment failure (relapse after
Auto transplantation and TRM after URD transplantation)
yielded similar DFS rates for patients choosing either trans-
plantation approach, with an approximately 40% DFS in
CR1 and 30% DFS in CR2. However, patients with favorable
features (higher Karnofsky scores, longer initial remission,
and lower diagnostic WBC) had notably improved DFS rates
compared to patients lacking these clinical features. In this
favorable group, URD BMT yielded better DFS rates than
did Auto transplantation in both older and younger patients.
An earlier analysis of similar data compared multicenter
URD transplantation with purged autografts performed at the
University of Minnesota and the Dana Farber Cancer Insti-
tute [19]. In that report, superior DFS was observed for chil-
dren, male patients, and patients whose BMT was performed
during CR1 or CR2 compared to during more advanced dis-
ease. Both regression analyses and recursive partition analyses
could suggest only a trend toward an advantage for URD ver-
sus Auto transplantation that was apparent only in patients
<18 years of age. Either approach yielded only 25% survival in
adult patients. A recent expert panel decision analysis also
offered no clear consensus about the best choice of transplan-
tation options for ALL patients [29]. Recent French and Med-
ical Research Council–Eastern Cooperative Oncology Group
comparative trials of related donor allografting versus auto-
grafting or chemotherapy suggest that related donor allograft-
ing yields superior outcomes [30,31], but other comparative
data regarding URD BMT are unavailable.
Clinical decision making about these 2 options, there-
fore, must still be guided by features that are suggestively,
but not deﬁnitively, shown to yield superior outcomes. Fea-
tures indicating high-risk leukemia (karyotype, extreme
leukocytosis, short initial remission) require improved
antileukemic effects for both URD and Auto transplanta-
tion. Patients with lesser risk factors may beneﬁt from the
more potent effects of URD BMT. Conversely, patients
with compromised performance status may benefit from
alternative nontransplantation approaches or from less
intense nonmyeloablative allografting. Intensified condi-
tioning regimens [7], graft purging [11-13], the use of
peripheral blood progenitor cells or posttransplantation
antileukemic chemotherapy [14], or immunotherapy [32,33]
might further enhance the efﬁcacy of autograft approaches.
Clinical improvement in both approaches as well as addi-
tional study will be needed to deﬁne patient subsets display-
ing a risk-factor phenotype clearly best served by one or the
other of these 2 transplantation techniques.
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